ASH 2019 | Fracture risk in older DLBCL patients after R-CHOP
Diffuse large B-cell lymphoma (DLBCL) and osteoporotic fracture occur more frequently in older patients. Steroids and chemotherapy are recognized as a risk factor for fragility-related fractures. Graham Collins, MA, MBBS, MRCP, FRCPath, DPhil, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, discusses a study designed to better define the risk of fracture following front line R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone) immunochemotherapy in older patients with DLBCL. Data shows there is a clinically relevant fracture risk in older DLBCL patients specifically receiving R-CHOP in early follow-up. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
